Globus Medical, Inc. $GMED Stock: Leeward Investments LLC MA Cuts Stake

Leeward Investments LLC MA reduced its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 5.7% in the third quarter, Holdings Channel reports. The institutional investor owned 154,919 shares of the medical device company’s stock after selling 9,408 shares during the period. Leeward Investments LLC MA’s holdings in Globus Medical were worth $11,603,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. Paradigm Capital Management Inc. NY bought a new position in Globus Medical in the 2nd quarter worth $70,042,000. American Capital Management Inc. bought a new stake in Globus Medical during the second quarter valued at about $51,599,000. Hawk Ridge Capital Management LP bought a new stake in Globus Medical during the first quarter valued at about $43,078,000. Arrowstreet Capital Limited Partnership grew its holdings in Globus Medical by 107.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company’s stock valued at $78,656,000 after purchasing an additional 471,875 shares during the period. Finally, Janus Henderson Group PLC increased its position in Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after buying an additional 328,217 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director James R. Tobin sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the completion of the sale, the director directly owned 15,000 shares of the company’s stock, valued at $1,118,700. This trade represents a 66.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Stephen Zarrilli sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the sale, the director directly owned 25,000 shares of the company’s stock, valued at $2,176,000. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 18.38% of the company’s stock.

Wall Street Analyst Weigh In

GMED has been the topic of several recent research reports. UBS Group began coverage on Globus Medical in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price objective on the stock. Wells Fargo & Company lowered their price objective on Globus Medical from $103.00 to $99.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Royal Bank Of Canada cut their price objective on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research note on Thursday, October 1st. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a report on Friday, September 18th. Finally, Truist Financial reduced their target price on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a report on Thursday, July 16th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $99.46.

Globus Medical Trading Up 0.1%

Shares of GMED stock opened at $81.47 on Monday. The stock has a market capitalization of $10.94 billion, a price-to-earnings ratio of 20.84, a price-to-earnings-growth ratio of 1.31 and a beta of 0.96. Globus Medical, Inc. has a 12-month low of $59.51 and a 12-month high of $101.40. The stock’s 50-day moving average price is $78.03 and its 200-day moving average price is $81.14.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.24. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The company had revenue of $789.61 million for the quarter, compared to analysts’ expectations of $782.88 million. During the same quarter in the previous year, the business posted $0.86 earnings per share. Globus Medical’s quarterly revenue was up 5.9% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, research analysts predict that Globus Medical, Inc. will post 4.99 EPS for the current fiscal year.

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.